UCB (UCB.BR)
Makes medicines for brain disorders, immune diseases, and epilepsy seizures
250.20+0.02%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+35.4%
The outlook
UCB trades at €250.20 with analyst consensus leaning Buy across 19 analysts, and the average price target sits roughly 15% above the current level. The stock sits in the upper half of its 52-week range but shows mixed momentum relative to its moving averages, reflecting a cautious intermediate trend despite the overall bullish lean.
What’s behind the score
Analyst consensusBuy — 1.8 avg of 19 analysts
Price trendMixed vs its moving averages
52-week range64% of the way from its 52-week low to high
Price targetAvg target +15% vs current price
Analyst price target
~12-month · 19 analysts287.95average target+15.1% vs now
Now 250.20
Low 195.00High 340.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
—
52-wk high
289.50
52-wk low
180.35
50-day avg
250.32
200-day avg
248.85
Trailing P/E
31.1